Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Downclassifies Multiplex Nucleic Acid Assays

This article was originally published in The Gray Sheet

Executive Summary

FDA has decided to relax its classification of multiplex nucleic acid assays to detect microorganisms and resistance markers in the blood but with special controls to mitigate concerns with potential to misinterpret test results.

You may also be interested in...



Guidance On Nucleic Acid-Based IVDs Recommends Analytical, Clinical Studies

An FDA final guidance released Aug. 27 on highly multiplexed microbiological in vitro nucleic-acid based diagnostics recommends studies on both the analytical and clinical performance of the devices.

New Products In Brief

New assays and devices on the market include Roche’s cytomegalovirus viral load test, Nanosphere’s infectious disease assay.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

Related Companies

UsernamePublicRestriction

Register

MT033941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel